Low thyroid function is associated with an increased risk of advanced fibrosis in patients with metabolic dysfunction-associated fatty liver disease

被引:6
|
作者
Fan, Hong [1 ,2 ,3 ,4 ]
Li, Lili [1 ,2 ,5 ]
Liu, Zhenqiu [4 ,6 ,7 ,8 ]
Zhang, Pengyan [1 ,2 ,3 ,4 ]
Wu, Sheng [1 ,2 ,3 ]
Han, Xinyu [1 ,2 ,3 ]
Chen, Xingdong [3 ,4 ,6 ,7 ,8 ]
Suo, Chen [1 ,2 ,3 ,4 ]
Cao, Liou [5 ]
Zhang, Tiejun [1 ,2 ,3 ,4 ]
机构
[1] Fudan Univ, Sch Publ Hlth, Dept Epidemiol, Shanghai 200032, Peoples R China
[2] Fudan Univ, Key Lab Publ Hlth Safety, Minist Educ, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai Inst Infect Dis & Biosecur, Sch Publ Hlth, Shanghai, Peoples R China
[4] Fudan Univ, Taizhou Inst Hlth Sci, Taizhou, Peoples R China
[5] Affiliated Shanghai Univ Med & Hlth Sci, Jiading Dist Cent Hosp, Shanghai 200032, Peoples R China
[6] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200438, Peoples R China
[7] Fudan Univ, Collaborat Innovat Ctr Genet & Dev, Sch Life Sci, Shanghai 200438, Peoples R China
[8] Fudan Univ, Human Phenome Inst, 825 Zhangheng Rd, Shanghai, Peoples R China
关键词
Fatty liver disease; MAFLD; Fibrosis; Low-normal thyroid function; Subclinical hypothyroidism; NONALCOHOLIC STEATOHEPATITIS; SUBCLINICAL HYPOTHYROIDISM; EUTHYROID SUBJECTS; NATIONAL-HEALTH; HORMONES; NAFLD;
D O I
10.1186/s12876-022-02612-3
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aims Observational studies showed that low thyroid function may perturb liver function. We aimed to evaluate the association of low thyroid function with both metabolic dysfunction-associated fatty liver disease (MAFLD) and advanced hepatic fibrosis.Methods Participants who underwent abdominal ultrasonography and thyroid function test in a Chinese hospital from 2015 to 2021were enrolled. Fibrosis-4 index (FIB-4) > 2.67 and/or non-alcoholic fatty liver disease fibrosis score (NFS) > 0.676 were used to define advanced fibrosis. Descriptive analyses were performed to characterize the epidemiology of MAFLD according to levels of thyroid-stimulating hormone (TSH). The logistic regression model was applied to estimate the association of low thyroid function with MAFLD and advanced fibrosis.Results A total of 19,946 participants (52.78% males, mean age: 47.31 years, 27.55% MAFLD) were included, among which 14,789 were strict-normal thyroid function, 4,328 were low-normal thyroid function, 829 were subclinical hypothyroidism. TSH levels were significantly higher in MAFLD patients with a FIB-4 > 2.67 and /or NFS > 0.676 than their counterparts. The logistic regression model adjusted for age and sex showed that low-normal thyroid function increased the risk of MAFLD (odds ratio [OR] = 1.09; 95% confidence interval [CI] 1.01-1.18). Multivariable regression model adjusted for age, sex, body mass index, type 2 diabetes, and hypertension showed low-normal thyroid function increased the risk of advanced fibrosis in patients with MAFLD (FIB-4 > 2.67: OR = 1.41, 95% CI 1.02-1.93; NFS > 0.676: OR = 1.72, 95% CI 1.08-2.72).Conclusion Elevated TSH concentrations are associated with advanced hepatic fibrosis, even in the euthyroid state.
引用
收藏
页数:8
相关论文
共 50 条
  • [11] Impact of Thyroid Function on the Prevalence and Mortality of Metabolic Dysfunction-Associated Fatty Liver Disease
    Chen, Yu-ling
    Tian, Shen
    Wu, Juan
    Li, Hao
    Li, Shu
    Xu, Zhou
    Liang, Xin-yu
    Adhikari, Vishnu Prasad
    Xiao, Jun
    Song, Jing-yu
    Ma, Chen-yu
    She, Rui-ling
    Li, Zhao-xing
    Wu, Kai-nan
    Kong, Ling-quan
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (07): : E434 - E443
  • [12] Low-Normal Thyroid Function Is Not Associated with Either Non-Alcoholic Fatty Liver Disease or with Metabolic Dysfunction-Associated Fatty Liver Disease
    Zuarth-Vazquez, Julia
    Moreno-Castaneda, Lidia
    Soriano-Marquez, Juan Pablo
    Velazquez-Aleman, Alain
    Ramos-Ostos, Martha Helena
    Uribe, Misael
    Lopez-Mendez, Ivan
    Juarez-Hernandez, Eva
    LIFE-BASEL, 2023, 13 (04):
  • [13] ASSOCIATION OF THE METABOLIC STATUS WITH THE PRESENCE OF ADVANCED LIVER FIBROSIS IN MEXICAN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE (MAFLD)
    Mendez-Guerrero, Osvely
    Cervera, Luis A. Chi
    Reyes, Raul Bernal
    Remes-Troche, Jose Maria
    Parra, Bryan Adrian Priego
    Vazquez, Sophia E. Martinez
    Amieva-Balmori, Mercedes
    Rodriguez, Leonardo A. Martinez
    Triana-Romero, Arturo
    Chavez, Maria E. Icaza
    GASTROENTEROLOGY, 2021, 160 (06) : S673 - S673
  • [14] Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Is Independently Associated With Reduced Renal Function
    Villarroel, Carolina
    Karim, Gres
    Sehmbhi, Mantej
    Debroff, Jake
    Weisberg, Ilan
    Dinani, Amreen
    GASTRO HEP ADVANCES, 2024, 3 (01): : 122 - 127
  • [15] LIVERSTAT for risk stratification for patients with metabolic dysfunction-associated fatty liver disease
    Leow, Yong Wen
    Chan, Wah Loong
    Lai, Lee Lee
    Mustapha, Nik Raihan Nik
    Mahadeva, Sanjiv
    Quiambao, Ronald
    Munteanu, Mona
    Chan, Wah Kheong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (10) : 2182 - 2189
  • [16] Comment on "Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease"
    Chen, Yu-Syuan
    Hung, Yao-Min
    Wei, James Cheng-Chung
    JOURNAL OF HEPATOLOGY, 2022, 77 (01) : 259 - 260
  • [17] Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea
    Kim, Mimi
    Yoon, Eileen L.
    Cho, Seon
    Lee, Chul-min
    Kang, Bo-Kyeong
    Park, Huiyul
    Jun, Dae Won
    Nah, Eun-Hee
    LIVER INTERNATIONAL, 2022, 42 (07) : 1536 - 1544
  • [18] The nonlinear relationship between thyroid function parameters and metabolic dysfunction-associated fatty liver disease
    Hu, Yingying
    Zhou, Fan
    Lei, Fang
    Lin, Lijin
    Huang, Xuewei
    Sun, Tao
    Liu, Weifang
    Zhang, Xingyuan
    Cai, Jingjing
    She, Zhi-Gang
    Li, Hongliang
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [19] A screening study of high-risk groups for liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease
    Chao, Guanqun
    Zhu, Yue
    Bao, Yang
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [20] Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
    Kani, Haluk Tarik
    Demirtas, Coskun Ozer
    Keklikkiran, Caglayan
    Ergenc, Ilkay
    Mehdiyev, Shahin
    Akdeniz, Esra
    Yilmaz, Yusuf
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2021, 32 (08): : 661 - 666